Brief: Cytomx Therapeutics Says On Aug 22, Entered Into Transition Agreement With Abbvie Global Enterprises Ltd.
24/08/2023 22:32
Aug 24 (Reuters) - Abbvie Inc ABBV.N :
* CYTOMX THERAPEUTICS INC- ON AUG 22, ENTERED INTO
TRANSITION
AGREEMENT WITH ABBVIE GLOBAL ENTERPRISES LTD.
* CYTOMX THERAPEUTICS- PURSUANT TO DEAL WITH ABBVIE GLOBAL
ENTERPRISES LTD, CO REGAINED EXCLUSIVE WORLDWIDE RIGHTS TO
DEVELOP CX-2029
* CYTOMX THERAPEUTICS: PURSUANT TO DEAL, ABBVIE ELIGIBLE TO
RECEIVE TIERED SALES ROYALTIES FOR CX-2029 RANGING FROM
LOW-TO-MID SINGLE DIGIT PERCENTAGES
Source text for Eikon: ID:
Further company coverage: ABBV.N
((Reuters.Brief@thomsonreuters.com;))
Recent news on CytomX Therapeutics
See all newsCytomX Q2 revenue misses, partly hurt by lower research activities in the Astellas collaboration
CytomX Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Cytomx Therapeutics Announces Appointment Of Charles Fuchs, M.D., M.P.H., To The Board Of Directors
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway